FY2023 Earnings Forecast for Curis, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2023 earnings estimates for shares of Curis in a note issued to investors on Tuesday, March 14th. Cantor Fitzgerald analyst L. Watsek expects that the biotechnology company will earn ($0.44) per share for the year. The consensus estimate for Curis’ current full-year earnings is ($0.42) per share.

Separately, StockNews.com started coverage on shares of Curis in a research note on Thursday. They set a “hold” rating on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Curis presently has an average rating of “Moderate Buy” and a consensus price target of $9.50.

Curis Trading Down 3.8 %

Shares of CRIS stock opened at $0.54 on Friday. The stock has a market capitalization of $52.13 million, a P/E ratio of -0.88 and a beta of 2.88. The firm’s 50 day moving average is $0.69 and its 200 day moving average is $0.73. Curis has a 12 month low of $0.47 and a 12 month high of $2.90.

Curis (NASDAQ:CRIS – Get Rating) last released its earnings results on Monday, March 13th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. The firm had revenue of $2.89 million for the quarter, compared to analysts’ expectations of $3.03 million. Curis had a negative net margin of 557.68% and a negative return on equity of 94.33%. During the same period in the previous year, the company earned ($0.15) earnings per share.

Institutional Investors Weigh In On Curis

Several institutional investors have recently added to or reduced their stakes in CRIS. BlackRock Inc. lifted its position in shares of Curis by 4.9% in the 1st quarter. BlackRock Inc. now owns 6,587,381 shares of the biotechnology company’s stock worth $15,677,000 after purchasing an additional 306,340 shares during the period. Vanguard Group Inc. grew its stake in shares of Curis by 0.9% in the first quarter. Vanguard Group Inc. now owns 4,241,608 shares of the biotechnology company’s stock worth $10,095,000 after acquiring an additional 38,980 shares during the period. Nantahala Capital Management LLC grew its position in Curis by 46.4% during the second quarter. Nantahala Capital Management LLC now owns 3,628,162 shares of the biotechnology company’s stock valued at $3,572,000 after buying an additional 1,149,897 shares during the period. Renaissance Technologies LLC grew its position in Curis by 81.5% during the second quarter. Renaissance Technologies LLC now owns 2,392,035 shares of the biotechnology company’s stock valued at $2,355,000 after buying an additional 1,073,835 shares during the period. Finally, Citigroup Inc. grew its position in Curis by 187,394.5% during the fourth quarter. Citigroup Inc. now owns 2,137,437 shares of the biotechnology company’s stock valued at $1,176,000 after buying an additional 2,136,297 shares during the period. Hedge funds and other institutional investors own 38.72% of the company’s stock.

Curis Company Profile

(Get Rating)

Curis, Inc engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.